TrialOncotarget2016

Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide GP2 vaccine in breast cancer patients to prevent recurrence.

Elizabeth A Mittendorf et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.